177.89
3.79 (2.18%)
| Previous Close | 174.10 |
| Open | 176.09 |
| Volume | 234,442 |
| Avg. Volume (3M) | 1,211,616 |
| Market Cap | 17,886,836,736 |
| Price / Earnings (TTM) | 27.37 |
| Price / Earnings (Forward) | 23.70 |
| Price / Sales | 5.55 |
| Price / Book | 4.95 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.75 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIPPOLDT DARIN | - | 169.26 | -10,000 | -1,699,704 |
| Aggregate Net Quantity | -10,000 | |||
| Aggregate Net Value ($) | -1,699,704 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 169.26 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIPPOLDT DARIN | Officer | 29 Jun 2026 | Automatic sell (-) | 9,800 | 170.00 | 1,666,000 |
| LIPPOLDT DARIN | Officer | 29 Jun 2026 | Option execute | 9,800 | - | - |
| LIPPOLDT DARIN | Officer | 26 Jun 2026 | Automatic sell (-) | 200 | 168.52 | 33,704 |
| LIPPOLDT DARIN | Officer | 26 Jun 2026 | Option execute | 200 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |